| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
Because of its bitter taste, sucrose octaacetate is non-toxic and has a wide range of uses. For instance, sucrose octaacetate at a concentration of 0.06% (w/w) becomes excessively bitter when ingested. There are 255 distinct isomers and breakdown products that sucrose octaacetate can generate, and they all have extremely low molar absorptivities [1]. 2 and 3 g of sucrose octaacetate were used to create polyaniline (PANI) nanofibers and nanorods, respectively. An increase in sucrose octaacetate concentration led to the observation of nanostructures with irregularly formed agglomerates, such as particles and scaffolds. The molecular structure of the resultant polyaniline remains unaffected by the presence of sucrose octaacetate during the polymerization process, only causing morphological modifications. Due to its increased crystallinity, highly ordered structure, and electrical conductivity, 2 g of sucrose octaacetate-polymerized PANI exhibits higher thermal stability than 1, 3, and 4 g of PANI produced from sucrose octaacetate [3].
|
|---|---|
| ln Vivo |
No recombination between the sucrose octaacetate avoidance phenotype and the PRP haplotype was detected in any mouse population. Therefore, Soa and Prp are either very near or identical. To examine the latter hypothesis, two type A proline-rich protein genes (MP2 and M14) (∼30 kb apart at the Prp locus) were separately separated from a sucrose octaacetate taster inbred strain ( SWR) were transplanted to sucrose octaacetate-non-taste inbred line (FVB). In a two-bottle test, 5 MP2 transgenic mice and 7 M14 transgenic mice were insensitive to 1 mM sucrose octaacetate, thereby keeping the non-taste FVB phenotype. Expression of type A Prp gene mRNA alone or combined does not enhance SOA taste sensitivity in non-taster mice [2].
|
| References |
|
| Additional Infomation |
Sucrose octaacetate is a glycoside.
Sucrose octaacetate has been reported in Planchonella vitiensis with data available. |
| Molecular Formula |
C28H38O19
|
|---|---|
| Molecular Weight |
678.59
|
| Exact Mass |
678.2
|
| CAS # |
126-14-7
|
| PubChem CID |
31340
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
668.3±55.0 °C at 760 mmHg
|
| Melting Point |
82-85 °C(lit.)
|
| Flash Point |
275.0±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.509
|
| LogP |
3.19
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
47
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
FC(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC1C(=C([H])C(C(=O)OC([H])([H])C([H])([H])C(C2C([H])=C(C3=C(C=2[H])C(C2C([H])=C(C([H])=C(C3=2)[N+](=O)[O-])[N+](=O)[O-])=O)[N+](=O)[O-])=O)=C([H])C=1OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)F.O=C=C([H])[H]
|
| InChi Key |
ZIJKGAXBCRWEOL-SAXBRCJISA-N
|
| InChi Code |
InChI=1S/C28H38O19/c1-12(29)37-9-20-22(40-15(4)32)24(42-17(6)34)25(43-18(7)35)27(45-20)47-28(11-39-14(3)31)26(44-19(8)36)23(41-16(5)33)21(46-28)10-38-13(2)30/h20-27H,9-11H2,1-8H3/t20-,21-,22-,23-,24+,25-,26+,27-,28+/m1/s1
|
| Chemical Name |
[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[(2S,3S,4R,5R)-3,4-diacetyloxy-2,5-bis(acetyloxymethyl)oxolan-2-yl]oxyoxan-2-yl]methyl acetate
|
| Synonyms |
NSC-1695; NSC 1695; Sucrose octaacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~147.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4736 mL | 7.3682 mL | 14.7364 mL | |
| 5 mM | 0.2947 mL | 1.4736 mL | 2.9473 mL | |
| 10 mM | 0.1474 mL | 0.7368 mL | 1.4736 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
